Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Director dealings: AstraZeneca CFO makes $1.5m sale, IHG chair buys in

Tue, 09th May 2023 14:28

(Sharecast News) - At the top of the list of FTSE 350 director sells on Tuesday was AstraZeneca, whose chief financial officer sold almost $1.5m worth of the company's American depositary shares.

The pharmaceuticals giant said Aradhana Sarin sold 19,470 of the shares on 5 May, at a price of $74.81 each.

That valued the transaction at a total of $1,456,550.70.

Two of AstraZeneca's American depositary shares are equivalent to one of its ordinary shares, the firm said in its disclosure.

On the buying side of things, the non-executive chair of InterContinental Hotels Group was also dealing in American depositary instruments, spending almost $0.35m.

The owner of brands including Holiday Inn said Deanna Oppenheimer acquired 5,000 of its American depositary receipts on the New York Stock Exchange on 8 May.

Oppenheimer paid $68.89 for each ADR, valuing the purchase at $344,450 in total.

At 1437 BST, shares in AstraZeneca were up 0.11% in London at 11,884p, while those in InterContinental Hotels Group were 0.6% firmer at 5,442p.

Reporting by Josh White for Sharecast.com.

DIRECTOR SELLS

Company: AstraZeneca

Name: Aradhana Sarin

Volume: 19,470

Price: $74.81

Value: $1,456,550.70

Company: London Stock Exchange Group

Name: York Holdings II

Volume: 9,048

Price: 8,359.77p

Value: £756,391.99

DIRECTOR BUYS

Company: InterContinental Hotels Group

Name: Deanna Oppenheimer

Volume: 5,000

Price: $68.89

Value: $344,450.00

Company: CRH

Name: Christina Verchere

Volume: 1,000

Price: 3,824.4p

Value: £38,244.00

Company: Videndum

Name: Andrea Rigamonti

Volume: 3,500

Price: 789.86p

Value: £27,645.07

Company: InterContinental Hotels Group

Name: Graham Allan

Volume: 300

Price: 5,418.36p

Value: £16,255.09

Company: Marshalls

Name: Martyn Coffey

Volume: 10,000

Price: 156p

Value: £15,600.00

Company: InterContinental Hotels Group

Name: Duriya Farooqui

Volume: 200

Price: $68.625

Value: $13,725.00

Company: InterContinental Hotels Group

Name: Daniela Barone Soares

Volume: 150

Price: 5,427.55p

Value: £8,141.33

Company: Marshalls

Name: Alison Lockwood

Volume: 3,763

Price: 164p

Value: £6,171.32

Company: Marshalls

Name: Amanda Bourne

Volume: 1,062

Price: 280p

Value: £2,973.60

Company: CMC Markets

Name: Euan William Marshall

Volume: 164

Price: 181.99p

Value: £298.46

Company: CMC Markets

Name: David John Fineberg

Volume: 164

Price: 181.99p

Value: £298.46

Company: Moneysupermarket.com Group

Name: Matthew Cresswell

Volume: 56

Price: 267.3p

Value: £149.69

Company: Moneysupermarket.com Group

Name: Peter Duffy

Volume: 56

Price: 267.3p

Value: £149.69

Company: Moneysupermarket.com Group

Name: Matthew Whittle

Volume: 38

Price: 267.3p

Value: £101.57

Related Shares

More News
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca a...

26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar...

25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.